Corrigendum to “Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT-EP)” [Lung Cancer 186 (2023) 107426] (Lung Cancer (2023) 186, (S0169500223009649), (10.1016/j.lungcan.2023.107426))

Yoshihiko Sakata, Go Saito, Shinya Sakata, Yuko Oya, Motohiro Tamiya, Hidekazu Suzuki, Ryota Shibaki, Asuka Okada, Toshihide Yokoyama, Hirotaka Matsumoto, Taiichiro Otsuki, Yuki Sato, Uchida Junji, Yoko Tsukita, Megumi Inaba, Hideki Ikeda, Daisuke Arai, Hirotaka Maruyama, Satoshi Hara, Shinsuke TsumuraJun Morinaga, Takuro Sakagami

Research output: Contribution to journalComment/debatepeer-review

Fingerprint

Dive into the research topics of 'Corrigendum to “Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT-EP)” [Lung Cancer 186 (2023) 107426] (Lung Cancer (2023) 186, (S0169500223009649), (10.1016/j.lungcan.2023.107426))'. Together they form a unique fingerprint.

Keyphrases

Nursing and Health Professions

Agricultural and Biological Sciences